Guardant Health, Inc. is a leading molecular diagnostics company focused on enabling precision medicine through use of its proprietary blood-based assays, focused in the emerging liquid biopsy arena. The Company’s core Health Oncology Platform is designed to improve patient clinical outcomes, lower healthcare costs, and accelerate biopharmaceutical drug development to manage cancer across all stages of the disease — targeting a >$35 billion total addressable market. The Company’s platform is designed to address a major challenge in oncology: the limitations and time / cost intensity inherent to a tissue-based diagnostic approach.